Total Payments
$7,214
2024 Payments
$1,730
Companies
12
Transactions
46
Medicare Patients
1,159
Medicare Billing
$124,208
Payment Breakdown by Category
Research$2,903 (40.2%)
Food & Beverage$2,298 (31.9%)
Travel$1,413 (19.6%)
Other$600.00 (8.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,903 | 3 | 40.2% |
| Food and Beverage | $2,298 | 36 | 31.9% |
| Travel and Lodging | $1,413 | 5 | 19.6% |
| Honoraria | $600.00 | 2 | 8.3% |
Payments by Type
General
$4,311
43 transactions
Research
$2,903
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $2,903 | 3 | $0 (2023) |
| ModernaTX, Inc. | $1,713 | 10 | $0 (2024) |
| Allergan Inc. | $981.97 | 10 | $0 (2019) |
| Bard Access Systems, Inc. | $600.00 | 2 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $292.83 | 6 | $0 (2021) |
| Merck Sharp & Dohme LLC | $173.70 | 3 | $0 (2022) |
| PORTOLA PHARMACEUTICALS, INC. | $148.15 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $141.92 | 2 | $0 (2021) |
| Mallinckrodt LLC | $104.79 | 1 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $73.87 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,730 | 11 | ModernaTX, Inc. ($1,713) |
| 2023 | $2,903 | 3 | Eli Lilly and Company ($2,903) |
| 2022 | $63.70 | 2 | Merck Sharp & Dohme LLC ($63.70) |
| 2021 | $159.05 | 3 | AstraZeneca Pharmaceuticals LP ($141.92) |
| 2019 | $780.91 | 12 | Allergan Inc. ($470.75) |
| 2018 | $400.94 | 3 | Bard Access Systems, Inc. ($300.00) |
| 2017 | $1,176 | 12 | Allergan Inc. ($511.22) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/30/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $947.81 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $217.35 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $191.30 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $32.02 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $24.92 | General |
| 09/04/2023 | Eli Lilly and Company | — | — | In-kind items and services | $535.01 | Research |
| Study: A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | ||||||
| 07/14/2023 | Eli Lilly and Company | — | — | In-kind items and services | $865.46 | Research |
| Study: A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | ||||||
| 04/13/2023 | Eli Lilly and Company | — | — | In-kind items and services | $1,502.53 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 08/17/2022 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $34.94 | General |
| Category: VACCINE | ||||||
| 08/16/2022 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $28.76 | General |
| Category: VACCINE | ||||||
| 09/28/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.92 | General |
| 05/10/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/01/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/11/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/10/2019 | PORTOLA PHARMACEUTICALS, INC. | ANDEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $10.09 | General |
| Category: HEMATOLOGY/NEUROLOGY | ||||||
| 08/07/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/30/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $124.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/09/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/26/2019 | PORTOLA PHARMACEUTICALS, INC. | ANDEXXA (Biological) | Food and Beverage | Cash or cash equivalent | $14.99 | General |
| Category: HEMATOLOGY/NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $1,503 | 1 |
| A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | Eli Lilly and Company | $865.46 | 1 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $535.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 429 | 463 | $438,130 | $49,314 |
| 2020 | 5 | 730 | 803 | $689,738 | $74,894 |
Total Patients
1,159
Total Services
1,266
Medicare Billing
$124,208
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 140 | 145 | $203,000 | $21,416 | 10.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 92 | 98 | $147,000 | $19,468 | 13.2% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 56 | 71 | $66,385 | $6,708 | 10.1% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 14 | 19 | $12,255 | $965.43 | 7.9% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 127 | 130 | $9,490 | $757.15 | 8.0% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 233 | 257 | $359,800 | $35,787 | 9.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 151 | 154 | $231,000 | $30,189 | 13.1% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 58 | 63 | $58,905 | $5,446 | 9.2% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 262 | 301 | $21,973 | $1,969 | 9.0% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2020 | 26 | 28 | $18,060 | $1,504 | 8.3% |
About Deon Miller
Deon Miller is a Emergency Medicine healthcare provider based in Perth Amboy, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2013. The National Provider Identifier (NPI) number assigned to this provider is 1619310570.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Deon Miller has received a total of $7,214 in payments from pharmaceutical and medical device companies, with $1,730 received in 2024. These payments were reported across 46 transactions from 12 companies. The most common payment nature is "" ($2,903).
As a Medicare-enrolled provider, Miller has provided services to 1,159 Medicare beneficiaries, totaling 1,266 services with total Medicare billing of $124,208. Data is available for 2 years (2020–2021), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Location Perth Amboy, NJ
- Active Since 04/10/2013
- Last Updated 04/10/2013
- Taxonomy Code 207P00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619310570
Products in Payments
- DALVANCE (Drug) $383.95
- AVYCAZ (Drug) $355.39
- BAS-PowerGlide (Device) $300.00
- PICC & MIDLINE (Device) $300.00
- ENTRESTO (Drug) $292.83
- ANDEXXA (Biological) $148.15
- LOKELMA (Drug) $125.00
- SIVEXTRO (Drug) $110.00
- VRAYLAR (Drug) $107.69
- OFIRMEV (Drug) $104.79
- XARELTO (Drug) $73.87
- GIAPREZA (Drug) $68.19
- CAPVAXIVE (Biological) $63.70
- Kcentra (Biological) $12.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Perth Amboy
Dr. Dane Clarke, Md, MD
Emergency Medicine — Payments: $1,689
Emergency Medicine $1,689
Dr. Duane Dyson, Md, MD
Emergency Medicine — Payments: $695.96
Emergency Medicine $695.96
Dr. Zhimin Wang, Md, MD
Emergency Medicine — Payments: $245.00
Emergency Medicine $245.00
Dr. Peter Cheng, Md, MD
Emergency Medicine — Payments: $129.35
Emergency Medicine $129.35
Dr. Tyeese Gaines, D.o, D.O
Emergency Medicine — Payments: $76.89
Emergency Medicine $76.89
Hossam Radwan, M.d, M.D
Emergency Medicine — Payments: $56.53
Emergency Medicine $56.53